Ruifeng Chen

Ruifeng Chen

Auto-generated profile, based on publicly available information

Ruifeng Chen

Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla , CA , USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Radiology: Imaging Cancer
Verified
Journal Article
Closed access
FCFanny Chapelin
Fanny Chapelin
BLBenjamin I. Leach
Benjamin I. Leach
RCRuifeng Chen
Ruifeng Chen
DLDeanne Lister
Deanne Lister
KMKaren Messer
Karen Messer
EAEric T. Ahrens
Eric T. Ahrens
Fluorine 19 (19F) MRI enables temporal measurements of tumor cell oxygen tension in response to chimeric antigen receptor T-cell therapy; these data support the view that 19F partial pressure of ox... Purpose To assess the cell-specific, intracellular partial pressure of oxygen (Po2) dynamics of both tumor and chimeric antigen receptor (CAR) T cells in a murine immunotherapy model. Materials and...

11 July 2022 in The Oncologist
Verified
Journal Article
Open access
PDF file
RCRuifeng Chen
Ruifeng Chen
KHKasim Hakimi
Kasim Hakimi
XZXinlian Zhang
Xinlian Zhang
KMKaren Messer
Karen Messer
SPSandip Pravin Patel
Sandip Pravin Patel
Immune checkpoint blockade (ICB) has transformed cancer therapy, with long-term responses and a favorable safety profile; however, only a minority of patients respond. Response to ICB is influenced by immune-related genetic factors such as HLA haplotype, potentially including patient blood type and associated differences in diversity of the T-cell repertoire. A minority of patients experience immune-related adverse events (irAEs), with unclear relation to response or resistance. In this single institution study, we aimed to investigate the relationship of time to treatment failure (TTF) with patient blood type and with occurrence of irAEs, among patients with metastatic cancer receiving ICB. We found a strong association of improved TTF with presence of irAEs, and also among patients with type O blood, compared with type A/B/AB blood. Among patients with type O blood, TTF was substantially longer among those experiencing an irAE (n = 44; adjusted HR 0.41, 95% CI 0.18,0.96). For patients with type A/B/AB blood, no significant association was present (n = 63; adjusted HR 0.69, 95% CI 0.39,1.21). For type O patients, median TTF of ICB was 13.4 months (95% CI: 3.79 months, NA) vs 2.55 months (95% CI: 1.95 months, 4.95 months) for other patients. This retrospective study of a cohort of patients receiving ICB suggests a preferential benefit among patients with type O blood and, in particular, among patients with type O blood who developed irAEs. Validation in future independent cohorts and investigation of a potential biologic basis for this finding is warranted.